Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH)
Status:
Completed
Trial end date:
2016-11-28
Target enrollment:
Participant gender:
Summary
The use of hydroxyurea in sickle cell disease patients with glomerular hyperfiltration and
renal failure requires a specific monitoring and dose adjustment in order to remain within
the therapeutic interval while limiting the risk of toxicity or therapeutic failure. For this
reason the investigators propose to compare the pharmacokinetic parameters of hydroxyurea in
normal-renal function sickle cell patients to those of patients with glomerular
hyperfiltration or moderate renal failure.